Ocugen co-founder and CEO Shankar Musunuri, Ph.D. explains what biotech leaders can learn from the Philadelphia Eagles, an agile team with a championship mindset.

Driving growth in a family-owned pharma company requires a balance of progress and preservation, writes Merz Therapeutics CEO ...

On this week's episode of the Business of Biotech, Jennifer Hawks Bland, CEO of NewYorkBIO, shares insights on New York State's life sciences ecosystem while reflecting on her journey from Capitol ...

In this chapter of Business of Biotech episode 252, Alnylam Chief Commercial Officer Tolga Tanguler shares on the company's strategy to pivot its RNAi therapeutic applications from rare to large ...

Tolga Tanguler, EVP and Chief Commercial Officer at Alnylam Pharmaceuticals, discusses the global opportunity for the commercialization of RNAi therapies with host Ben Comer. Catch the full episode ...

Sometimes the key to making a breakthrough in research, in any field, is to look at the problem differently than anybody has ...

I’ve spent most of my career in life sciences, and like many in the field, I’ve seen how slow and cautious the industry can be when embracing new technology. It’s understandable. We work in a highly ...

<p>On this week&#39;s episode of the Business of Biotech, Barry Quart, CEO of Connect Biopharma, weighs in on the current state of engagement between drug developers and the FDA, and how that key ...

<p>Cuts to federal research funding at universities and research organizations are pushing academic scientists into life sciences entrepreneurship. Experts at Sidley offer tips for the transition.</p> ...

The annual BIO International Convention, held this year in Boston on June 16 through 19, is a choose-your-own-adventure kind of meeting. With educational programing, theme-based session tracks, one-on ...

The IRS has changed what must be reported upon filing a research and development (R&D) tax credit claim, and the impact is especially significant for the life sciences industry. The tax form used to ...

Smart money will find good ideas, and if you follow the money in biotech these days, that means looking to China. From January to mid-May 2025, Chinese biotechnology companies had announced licensing ...